Result of AGM

RNS Number : 2264P

Allergy Therapeutics PLC

07 February 2023

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

Result of Annual General Meeting

7 February 2023 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that all resolutions proposed at the 2022 Annual General Meeting ("AGM") held today were duly passed by shareholders on a show of hands.

Resolutions 1 to 10 (inclusive) were proposed as ordinary resolutions and resolution 11 was proposed as a special resolution. The results of the proxy votes received ahead of the meeting are outlined in the table below.

Resolution	For:	%age	Against:	%age	Total Votes Cast	% of ISC	Withheld
1. To re-elect Manual Llobet as a Director	220,438,209	99.55	438,504	0.20	220,876,713	32.52	112,037
To re-elect Cheryl MacDiarmid as a Director	220,433,972	99.55	448,778	0.20	220,882,750	32.53	106,000
3. To re-elect Anthony Parker as a Director	218,552,445	98.70	2,324,268	1.05	220,876,713	32.52	112,037
4. To re- elect Zheqing (Simon) Shen as a Director	218,556,682	98.70	2,326,068	1.05	220,882,750	32.53	106,000
5. To re-elect Mary Tavener as a Director	220,433,972	99.55	442,741	0.20	220,876,713	32.52	112,037
6. To re-elect Tunde Otulana as a Director	220,433,972	99.55	442,741	0.20	220,876,713	32.43	112,037
7. To re-elect Peter Jensen as a Director	217,599,392	98.55	2,641,372	1.20	220,240,764	32.43	747,986
8. To re-appoint BDO LLP as auditors of the Company	218,640,401	99.63	235,796	0.11	218,876,197	32.23	2,112,553
9. To authorise the Directors to agree the Auditors remuneration	217,956,401	99.31	938,759	0.43	218,895,160	32.23	2,093,590
10. To authorise the Directors to allot the unissued share capital up to a specific amount (s.551)	220,517,191	99.58	366,559	0.17	220,883,750	32.53	105,000
11. Special Resolution: To adopt the Articles of Association	220,515,891	99.60	336,822	0.15	220,852,713	32.52	136,037

- ENDS -

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

Panmure Gordon (Nominated Adviser and Broker)

[phone]

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / David Daley / Davide Salvi

[e-mail]

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com .

 

END

 

 

RAGSSAFAWEDSEEE